bluebird bio Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : bluebird bio Inc.

BLUE 4.970

0.0%

Jun 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biotech Jim who wrote (22)	12/7/2013 6:42:00 PM
From: Biotech Jim	of 163

Adaptimmune, a British company, is also a player in CAR T technologies, but specifically they use engineered, increased affinity T cell receptor as the means of strengthening natural patient T cell responses with the goal to overcome tolerance to cancer. adaptimmune.com They have a cell manufacturing agreement with the Neostem subsidiary, Progenitor Cell Therapy. adaptimmune.com Adaptimmune has an exclusive license with Life Technologies Corporation on a proprietary manufacturing process for T cell therapy using its modified T cell receptors. The technology used is Life’s Dynabeads® CD3/CD28 CTS™, which are the only GMP-grade reagents commercially available for use in clinical trials practicing these patented methods for the rapid expansion of autologous T cells in T cell therapy. adaptimmune.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next